Elevar Therapeutics announced Friday that the U.S. Food and Drug Administration has turned down its application to approve a drug combination intended to treat a form of liver cancer.
According to the company, the FDA’s decision was based on problems identified during an inspection of one of its manufacturing sites, with regulators determining those deficiencies were significant enough to block approval.
